Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting on new treatments for patients with multiple myeloma. Topics of interest include chimeric antigen receptor (CAR) T-cell therapy, the anti-CS1 humanised monoclonal antibody, elotuzumab, lenalidomide maintenance therapy, first-line treatment of newly diagnosed multiple myeloma using lenalidomide plus dexamethasone, and the histone deacetylase (HDAC) inhibitor, panobinostat.
Allergy & Immunology
